Imaging With a Radio Tracer to Guide VT Ablations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01250912
Recruitment Status : Completed
First Posted : December 1, 2010
Last Update Posted : April 6, 2018
GE Healthcare
Information provided by (Responsible Party):
Timm-Michael Dickfeld, University of Maryland

Brief Summary:
Some patients are at risk for life-threatening fast heart rates. These can frequently be treated by using a catheter inside the heart to burn away the cells that create the fast heart rates. The purpose of this study is to image the nerves inside the heart of those patients. The investigators want to find out if abnormalities in the nervous system in the heart can help the physician to find the area that needs to be burnt away.

Condition or disease Intervention/treatment Phase
Ventricular Tachycardia Arrhythmia Drug: 123I-metaiodobenzylguanidine Not Applicable

Detailed Description:

Ventricular tachycardia is the next frontier in cardiology. Patients that have scar in the heart (for example after heart attacks) are at an increased risk of developing ventricular tachycardia. In these patients ventricular tachycardia represents an electrical wave front that circulates in the heart muscle using the scar in the heart. An increasing number of patients with ventricular tachycardia require cauterization (burning away) of the tissue to treat this life-threatening condition. The goal of this cauterization or ablation is to destroy "highways of surviving tissue" inside the scar, that allow ventricular tachycardia to exist. However, this can be very lengthy procedure (>5 hours) that has only a moderate success in the long run. Therefore, new treatment approaches are needed to make this procedure better.

The purpose of this study is to assess if radio tracers showing the nerve distribution in the heart (cardiac innervation) can be used in addition to the current technology ("voltage mapping") to identify the area that needs to be ablated (burnt away) to treat life-threatening fast heart rates (ventricular tachycardia)

Certain patterns of nerve distribution in the heart (sympathetic cardiac innervation) have been shown to predict outcome for different heart diseases, like heart transplant, coronary artery disease, heart failure, arrhythmias. One substance that allows visualization of the cardiac innervation is 123I-metaiodobenzylguanidine (123I-MIBG), which could provide additional information to understand and treat ventricular tachycardia.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations
Study Start Date : March 2010
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Imaging Tracer
No arms, the Radio tracer will be used in all subjects imaging tests.
Drug: 123I-metaiodobenzylguanidine
FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
Other Name: MIGB

Primary Outcome Measures :
  1. Imaging of Nerve distribution in heart [ Time Frame: 6 months after procedure ]
    Specific Aim 1: Evaluate if areas of left ventrical (LV) denervation measured by cardiac 123I-metaiodobenzylguanidine (MIBG) SPECT imaging (innervation map) can be integrated into the CartoXP electrophysiology mapping system. Participants will be followed for 6 months for an episode of Ventricular Tachycardia.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with ventricular arrhythmias requiring VT Ablation
  • Patients must be 18 years of age or older
  • Patient must be able to sign consent form
  • Patient must be willing to come back for the 6 month visit for additional study procedures

Exclusion Criteria:

  • Patient under 18 years old
  • Inability to sign consent
  • Pregnant Women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01250912

United States, Maryland
University of Maryland Medical Center, EP Lab, Rm. N3W77
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
University of Maryland
GE Healthcare
Principal Investigator: Timm R Dickfeld, MD,Ph.D University of Maryland

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Timm-Michael Dickfeld, Professor of Medicine, University of Maryland Identifier: NCT01250912     History of Changes
Other Study ID Numbers: HP-00043324
First Posted: December 1, 2010    Key Record Dates
Last Update Posted: April 6, 2018
Last Verified: April 2018

Keywords provided by Timm-Michael Dickfeld, University of Maryland:

Additional relevant MeSH terms:
Tachycardia, Ventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action